Articles, Explainers, Milestones

Discover how patient-derived organoids can be applied throughout the oncology drug development pipeline, demonstrated in colorectal cancer research.

Discover how patient-derived organoids can be applied throughout the oncology drug development pipeline, demonstrated in colorectal cancer research.

As gene editing advances, legacy off-target screening approaches are struggling to keep pace with increasing biological and regulatory complexity.

As discovery programs grow in complexity and throughput demands accelerate, automation has moved from a convenience to a core requirement for generating reliable, reproducible data at scale.

As multiplexing platforms become more scalable and flexible, biomarkers are playing an increasingly central role in both preclinical and clinical decision-making.

As bioprocess intensification pushes cell densities higher, engineering the right agitation strategy becomes the critical factor separating productive runs from failed batches.

Alternating tangential flow upstream integration unlocks continuous high-density perfusion by eliminating the cell retention bottlenecks that limit fed-batch productivity.

The plastic touching your drug product must be proven safe for patients. USP Chapter 665 became mandatory in May 2026. Here is what compliance now requires.

Perfusion bioreactors have become the backbone of high-yield bioproduction, enabling cell densities far beyond what fed-batch systems can achieve.

A missing sterile connector can stop an entire production campaign. Here is how well-designed single-use supply chains prevent that from happening.

Cleaning a stainless steel mixing tank between buffer preparations costs time, water, and validation overhead. Single-use mixing bags eliminate all three, and are redefining how multi-product facilities manage media and buffer throughput.

Process intensification and continuous bioprocessing are redefining what's possible in high-density cell culture and commercial biomanufacturing.